Regulatorische Updates
18. Sept. 2026•1 Min. Lesezeit
FDA Approves Levetiracetam (ANDA076920)
The FDA has approved ANDA076920 for Levetiracetam tablets (250 mg, 500 mg, 750 mg) manufactured by Dr. Reddy's Laboratories and sponsored by Pharmazone.
Regulatorische Updates
17. Sept. 2026•1 Min. Lesezeit
FDA Approves Mylan Generic Levetiracetam Tablets (ANDA 076919)
The FDA has approved Mylan Pharmaceuticals' generic levetiracetam tablets (250 mg, 500 mg, 750 mg) under ANDA 076919.
Regulatorische Updates
9. Sept. 2026•1 Min. Lesezeit
FDA Approves Lupin Generic Levetiracetam Tablets (ANDA 078154)
The FDA has approved Lupin Pharmaceuticals’ generic levetiracetam tablets in 250 mg, 500 mg, and 750 mg oral strengths under ANDA 078154.
Regulatorische Updates
4. Sept. 2026•1 Min. Lesezeit
FDA Approves Multiple Labeling Updates for Levetiracetam Oral Solution
The FDA has approved several labeling supplement submissions for the discontinued oral solution Levetiracetam (100 mg/mL) spanning from 2011 to 2024.
Regulatorische Updates
30. Aug. 2026•1 Min. Lesezeit
FDA Approves Levetiracetam Oral Solution (ANDA078976)
FDA has approved ANDA078976 for Levetiracetam oral solution, a prescription drug manufactured by Actavis Pharma, Inc., with a detailed submission history.
Regulatorische Updates
28. Aug. 2026•1 Min. Lesezeit
FDA Approves Generic Levetiracetam Tablets (ANDA078993)
The FDA has approved labeling for generic levetiracetam tablets, 250 mg to 1 g, from BluePoint Laboratories and Aurobindo Pharma.
Regulatorische Updates
26. Aug. 2026•1 Min. Lesezeit
FDA Approves ANDA078101 for Teva’s Levetiracetam Oral Tablets
The FDA has approved labeling submissions for Teva Pharm’s discontinued levetiracetam tablets (250 mg, 500 mg, 750 mg, 1 g) under ANDA078101.